Heartflow (NASDAQ:HTFL) Trading 8.4% Higher – Here’s What Happened

Shares of Heartflow, Inc. (NASDAQ:HTFL) rose 8.4% on Tuesday . The company traded as high as $22.46 and last traded at $22.39. Approximately 1,844,682 shares changed hands during mid-day trading, an increase of 21% from the average daily volume of 1,518,833 shares. The stock had previously closed at $20.66.

Analyst Ratings Changes

Several analysts recently issued reports on HTFL shares. Canaccord Genuity Group upped their price objective on shares of Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Stifel Nicolaus lifted their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Trading Up 7.8%

The company has a market cap of $1.90 billion and a PE ratio of -12.30. The business’s fifty day moving average is $29.74.

Insider Transactions at Heartflow

In related news, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52. Following the completion of the transaction, the chief executive officer directly owned 591,656 shares in the company, valued at $16,246,873.76. This trade represents a 3.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the sale, the insider owned 10,448,158 shares in the company, valued at $293,070,831.90. This trade represents a 16.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,030,562 shares of company stock worth $56,938,113 in the last 90 days.

Institutional Trading of Heartflow

A number of large investors have recently modified their holdings of HTFL. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the fourth quarter valued at $27,000. TFC Financial Management Inc. acquired a new stake in Heartflow in the 3rd quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new position in shares of Heartflow in the 4th quarter valued at about $45,000. Legal & General Group Plc purchased a new stake in shares of Heartflow during the third quarter worth approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow in the fourth quarter valued at approximately $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.